At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A MC, DB, Rand, Study to Evaluate Efficacy, Safety and Tolerability of Eze/Simva 10/40 mg, Atorva 40 mg, Rosuva 10 mg in Achieving LDL-C <2 mmol/l in Pts With CVD...on Simva 40 mg With LDL-C ³2 mmol/l
In Brief
A Phase 3 clinical trial evaluating ezetimibe (+) simvastatin, Comparator: atorvastatin, and 1 other intervention for Hypercholesterolemia. Completed, enrolled 786 participants.
Detailed Summary
To evaluate the percentage of patients with either established cardiovascular disease (CVD), at "high risk" of developing CVD or with diabetes who are on simvastatin 40mg, with fasting LDL-C \> 2mmol/l, who are able to attain the recommended LDL-C target of \< 2mmol/l following 6 weeks treatment with either ezetimibe/simvastatin 10/40mg, atorvastatin 40mg or rosuvastatin 10mg.
Study Details
Timeline
Interventions
ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.